ClinicalTrials.gg

Program

Ibuprofen

Also written as “ibuprofen”, “Intravenous ibuprofen” and “Ibuprofen/acetaminophen”.

Its studies are mostly in Pain · Pain, Postoperative · Osteoarthritis · Fever · Osteoarthritis, Knee, led by 36 companies.

Furthest: phase 4, since Aug 22, 2008101 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer150 open or runningphase 4since Aug 22, 2008Aug 22, 2008none ahead
Cumberland Pharmaceuticals90 open or runningphase 4since Apr 12, 2011Sep 22, 2005none ahead
Johnson & Johnson70 open or runningphase 4since Oct 14, 2005Oct 14, 2005none ahead
Boehringer Ingelheim60 open or runningphase 3since Aug 22, 2013Jul 26, 2010none ahead
Dr. Reddy's Laboratories60 open or runningphase 1since Jan 20, 2010Jan 20, 2010none ahead
Reckitt60 open or runningphase 3since Oct 26, 2010Oct 26, 2010none ahead
AFT Pharmaceuticals51 open or runningphase 3since Aug 16, 2011Apr 14, 2010Mar 2027phase 3 · NCT07225634
Strategic Science & Technologies40 open or runningphase 3since Oct 11, 2012Oct 11, 2012none ahead
Angelini Pharma30 open or runningphase 1since Jun 17, 2015Jun 17, 2015none ahead
GlaxoSmithKline30 open or runningphase 4since Mar 28, 2013Sep 5, 2006none ahead
Hypera Pharma30 open or runningphase 4since May 20, 2011Jul 28, 2010none ahead
Pierre Fabre30 open or runningphase 3since Feb 5, 2013Feb 10, 2012none ahead
Amgen20 open or runningphase 4since Mar 20, 2012Mar 19, 2007none ahead
Laboratorios Silanes S.A. de C.V.20 open or runningphase 3since Jul 18, 2024Jun 15, 2022none ahead
medherant-ltd20 open or runningphase 1since Aug 16, 2018Aug 16, 2018none ahead
Orion Corporation, Orion Pharma20 open or runningphase 3since Mar 22, 2012Mar 22, 2012none ahead
overseas-pharmaceuticals-ltd21 open or runningphase 3since Dec 20, 2021Feb 4, 2021none ahead
oxford-pharmascience-ltd20 open or runningphase 1since Aug 5, 2015Aug 5, 2015none ahead
perrigo-company20 open or runningphase 1since Dec 5, 2008Dec 5, 2008none ahead
Ache Laboratorios Farmaceuticos10 open or runningphase 3since Mar 8, 2016Mar 8, 2016none ahead
biochemics-inc10 open or runningphase 2since Dec 15, 2011Dec 15, 2011none ahead
biomendi-s-a-u10 open or runningphase 3since Sep 25, 2014Sep 25, 2014none ahead
futura-medical-developments-ltd10 open or runningphase 1since Jan 20, 2016Jan 20, 2016none ahead
future-sciene-technology10 open or runningphase 4since Dec 11, 2014Dec 11, 2014none ahead
HALEON10 open or runningphase 1since Dec 12, 2025Dec 12, 2025none ahead
Hamad Medical10 open or runningearly phase 1since Oct 7, 2019Oct 7, 2019none ahead
laborato-rio-teuto-brasileiro-s-a10 open or runningphase 3since Mar 22, 2011Mar 22, 2011none ahead
lahore-medical-research-center-llp10 open or runningphase 3since Feb 23, 2024Feb 23, 2024none ahead
Menarini Group10 open or runningphase 1since Jun 17, 2025Jun 17, 2025none ahead
Merck10 open or runningphase 1since Nov 28, 2007Nov 28, 2007none ahead
qc-kinetix-llc10 open or runningphase 2since Feb 6, 2023Feb 6, 2023none ahead
Sanofi10 open or runningphase 3since Aug 31, 2011Aug 31, 2011none ahead
scolr-pharma-inc10 open or runningphase 3since Jun 26, 2008Jun 26, 2008none ahead
simbec-research10 open or runningphase 1since Sep 16, 2014Sep 16, 2014none ahead
spherium-biomed10 open or runningphase 2since Nov 10, 2015Nov 10, 2015none ahead
x-pert-med-gmbh10 open or runningphase 1since Jan 22, 2010Jan 22, 2010none ahead

Also a collaborator on its studies: premier-research-group-plc, parexel, aptuit, cross-research-s-a, pharma-consulting-group-ab, pivotal-s-l and aaipharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 46 studies since Nov 3, 2011.

  1. Oct 25, 2018Phase 3 study in PainPfizer · NCT03722238 · 613 enrolled · United States
  2. Dec 17, 2018Phase 3 study in PainReckitt · NCT03785756 · 280 enrolled · United States
  3. Oct 7, 2019Hamad Medical's first study: early phase 1 study in FeverNew to Hamad MedicalHamad Medical · NCT04123717 · 147 enrolled · Qatar
  4. Feb 4, 2021overseas-pharmaceuticals-ltd's first study: phase 1 study in Chronic PainNew to overseas-pharmaceuticals-ltdoverseas-pharmaceuticals-ltd · NCT05329454 · 30 enrolled · China
  5. Aug 3, 2021Phase 3 study in Musculoskeletal PainHypera Pharma · NCT05013567 · 300 enrolled
  6. Dec 20, 2021Phase 3 study in Osteoarthritisoverseas-pharmaceuticals-ltd · NCT05318521 · 500 enrolled · United States, Taiwan
  7. Jun 15, 2022Laboratorios Silanes S.A. de C.V.'s first study: phase 1 study in PainNew to Laboratorios Silanes S.A. de C.V.Laboratorios Silanes S.A. de C.V. · NCT05428306 · 42 enrolled · Mexico
  8. Jul 27, 2022Phase 3 study in Tooth, ImpactedReckitt · NCT05484401 · 294 enrolled · United States
  9. Feb 6, 2023qc-kinetix-llc's first study: phase 2 study in Osteoarthritis, KneeNew to qc-kinetix-llcqc-kinetix-llc · NCT05742763 · United States
  10. Feb 23, 2024lahore-medical-research-center-llp's first study: phase 3 study in Primary DysmenorrheaNew to lahore-medical-research-center-llplahore-medical-research-center-llp · NCT06317064 · 40 enrolled · Pakistan
  11. Jul 18, 2024Phase 3 study in Common ColdLaboratorios Silanes S.A. de C.V. · NCT06531707 · 177 enrolled · Mexico
  12. Jun 17, 2025Menarini Group's first study: phase 1 study in Healthy Male and Female SubjectsNew to Menarini GroupMenarini Group · NCT07036861 · 74 enrolled · Lithuania
  13. Oct 30, 2025Phase 3 study in Acute PainAFT Pharmaceuticals · NCT07225634 · 60 planned · Hungary
  14. Dec 12, 2025HALEON's first study: phase 1 study in BioequivalenceNew to HALEONHALEON · NCT07345130 · 68 enrolled · United States

Ahead

  1. Mar 2027Primary completion: phase 3 study in Acute PainAFT Pharmaceuticals · NCT07225634

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

The newest 60 of 101 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07345130Bioequivalence · United States1CompletedHALEONFeb 3, 202668
NCT07225634Acute Pain · Hungary3RecruitingAFT PharmaceuticalsMar 202760
NCT07036861Healthy Male and Female Subjects · Lithuania1CompletedMenarini GroupApr 8, 202474
NCT06531707Common Cold · Mexico3CompletedLaboratorios Silanes S.A. de C.V.Jan 20, 2025177
NCT06317064Primary Dysmenorrhea · Pakistan3Completedlahore-medical-research-center-llpOct 31, 202440
NCT05742763Osteoarthritis, Knee · United States2Withdrawnqc-kinetix-llcOct 7, 20240
NCT05484401Tooth, Impacted · United States3CompletedReckittJun 15, 2023294
NCT05428306Pain · Mexico1CompletedLaboratorios Silanes S.A. de C.V.Nov 6, 201842
NCT05318521Osteoarthritis · United States, Taiwan3Active, not recruitingoverseas-pharmaceuticals-ltdAug 12, 2022500
NCT05013567Musculoskeletal Pain3UNKNOWNHypera PharmaMay 2023300
NCT05329454Chronic Pain · China1Completedoverseas-pharmaceuticals-ltdFeb 6, 202130
NCT04123717Fever · QatarEarly 1CompletedHamad MedicalMar 7, 2024147
NCT03785756Pain · United States3CompletedReckittFeb 20, 2020280
NCT03722238Pain · United States3TerminatedPfizerOct 28, 2019613
NCT03694587Healthy · Bulgaria1Completedmedherant-ltdOct 18, 201816
NCT03639571Healthy · Bulgaria1Completedmedherant-ltdOct 25, 201833
NCT03658720Healthy · United Kingdom–TerminatedReckittDec 21, 201729
NCT03496324Bioequivalence of the Test Formulation1CompletedReckittMay 6, 201624
NCT03497715Healthy Subjects1TerminatedReckittJul 30, 20156
NCT02974361Pharmacokinetics · United Kingdom1Completedoxford-pharmascience-ltdApr 28, 201730
NCT03003000Back Pain · Germany, Russian Federation3CompletedBoehringer IngelheimSep 24, 2017635
NCT02963701Healthy Volunteers · South Africa1CompletedBoehringer IngelheimJan 31, 201756
NCT02902302Healthy · Switzerland1CompletedAngelini PharmaJun 201660
NCT02902289Healthy · Switzerland1CompletedAngelini PharmaJul 201660
NCT02863575Pain · United States3CompletedPfizerApr 6, 2018374
NCT02761980Fever · United States3CompletedPfizerDec 6, 2017290
NCT02904304Common Cold · Brazil3SuspendedAche Laboratorios FarmaceuticosJul 2021150
NCT02689063Pain, Postoperative · United States3CompletedAFT PharmaceuticalsJun 30, 2017276
NCT02666846Pain · United Kingdom1Completedfutura-medical-developments-ltdMay 201560
NCT02912650Pain · United States3CompletedPfizerJun 2016568
NCT02602483Temporomandibular Joint Disorders · Spain2Completedspherium-biomedDec 201696
NCT02583399Pain · United States4CompletedCumberland PharmaceuticalsJul 2, 201930
NCT02597634Delayed Onset Muscle Soreness, DOMS · United States3CompletedStrategic Science & TechnologiesOct 2016156
NCT02521207Gastroduodenal Erosions · United Kingdom1Completedoxford-pharmascience-ltdAug 201553
NCT02482155Healthy · Switzerland1CompletedAngelini PharmaMar 201524
NCT02339129Delayed Onset Muscle Soreness · United States2CompletedStrategic Science & TechnologiesFeb 201572
NCT02327338Pain · United States4Completedfuture-sciene-technologyFeb 201590
NCT02294019Patient Compliance · United States3CompletedPfizerMay 2015738
NCT02254525Pain, Postoperative · Spain3Terminatedbiomendi-s-a-uJun 2014231
NCT02256423Healthy Volunteer Study · United Kingdom1Completedsimbec-researchAug 201424
NCT02183051Pain2CompletedBoehringer IngelheimOct 1998381
NCT01986660Healthy · United States1CompletedStrategic Science & TechnologiesOct 201314
NCT01929031Pain, Postoperative · United States3CompletedBoehringer IngelheimMar 2014562
NCT01901393Pain · United States4CompletedCumberland PharmaceuticalsAug 2014100
NCT01879371Healthy · Germany1CompletedBoehringer IngelheimJul 201336
NCT01859377Healthy Volunteers · Belgium1CompletedPierre FabreJun 201326
NCT01822665Gastrointestinal Mucosal Damage · United States4CompletedGlaxoSmithKlineJul 201228
NCT01785862Respiratory Tract Infections · France, Germany, Latvia and more3CompletedPierre FabreJun 2013427
NCT01771822Pain · United States1CompletedPfizerFeb 201350
NCT01874626Lymphoma, Follicular · United States3CompletedStrategic Science & TechnologiesJan 2014305
NCT01789606Agnosia · United States3CompletedPfizerJun 3, 20131,083
NCT01650519Arthroscopic Knee Surgery · United States4CompletedCumberland PharmaceuticalsDec 201251
NCT01563289Pain · Finland3CompletedOrion Corporation, Orion PharmaJul 201262
NCT01562717Pain · Finland3CompletedOrion Corporation, Orion PharmaOct 201262
NCT01563185Arthritis, Juvenile · United States4CompletedAmgenMar 201512
NCT01559259Pain · United States2CompletedPfizerSep 13, 2012394
NCT01555476Pain · Sweden1CompletedJohnson & JohnsonMar 201232
NCT01535079Respiratory Tract Infections · France, Germany, United Kingdom2CompletedPierre FabreNov 2012186
NCT01496326Osteoarthritis · Switzerland2Completedbiochemics-incAug 201175
NCT01466517Healthy · Brazil4CompletedPfizerNov 201170

How it is read

Names in the registry

  • “Ibuprofen”, 40 entries
  • “ibuprofen”, 10 entries
  • “Intravenous ibuprofen”, 5 entries
  • “Ibuprofen/acetaminophen”, 4 entries
  • “ibuprofen + caffeine”, 3 entries

Codes read as this program: SST0225.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.